Forsta AP Fonden increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,300 shares of the company’s stock after acquiring an additional 7,500 shares during the quarter. Forsta AP Fonden’s holdings in Zoetis were worth $28,779,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Webster Bank N. A. raised its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Quarry LP increased its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. LRI Investments LLC acquired a new position in Zoetis during the 1st quarter valued at approximately $43,000. Central Valley Advisors LLC acquired a new position in Zoetis during the 2nd quarter valued at approximately $49,000. Finally, EdgeRock Capital LLC acquired a new position in Zoetis during the 2nd quarter valued at approximately $56,000. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Performance
NYSE ZTS traded down $1.49 during mid-day trading on Friday, reaching $180.01. 2,623,220 shares of the stock were exchanged, compared to its average volume of 2,517,962. The business’s 50 day moving average is $189.18 and its 200-day moving average is $177.61. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a market capitalization of $82.14 billion, a P/E ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 33.14%.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $221.44.
Read Our Latest Stock Analysis on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Top Biotech Stocks: Exploring Innovation Opportunities
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.